Tag Archives: dyax

Shire Buying Rare-Disease Rival Dyax For $5.9 Billion

British drugmaker Shire (SHPG) agreed to pay $5.9 billion in cash for orphan-drug specialist Dyax (DYAX) Monday, sending the latter’s stock up sharply in early trading. Shire will pay $37.30 a share for Dyax, a premium of nearly 36% on Dyax’s Friday closing price. The deal includes a contingent value right (CVR) of $4 a share, or $646 million total, on Dyax’s drug candidate DX-2930, which is about to enter phase-three testing for hereditary

Dyax Soars As Rare-Disease Drug Wows Wall Street

Small biotech Dyax (DYAX) soared more than 52% to a 14-year high on the stock market Wednesday after it reported positive early-stage trial results for its rare-disease drug candidate late Tuesday. Dyax said its phase-one trial of DX-2930 showed positive safety and efficacy for 37 patients with hereditary angioedema (HAE), a rare, inheritable condition that leads to swelling of body parts, which is dangerous when it attacks such organs as the